葡萄糖类-1受体:治疗中的机制和进展
Zhikai Zheng1,2, Yao Zong3, Yiyang Ma1,2
1Department of Orthopaedics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China.
Signal transduction and targeted therapy
|September 17, 2024
概括
葡萄糖类-1 (GLP-1) 受体激活剂显示出超出糖尿病范围的广泛治疗潜力,为肥胖,心血管疾病和神经保护提供好处. 目前正在进行的研究扩大了它们对各种疾病的应用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 胃肠病学 胃肠病学
背景情况:
- 葡萄糖类-1 (GLP-1) 受体 (GLP-1R) 是一种与G蛋白结合的受体,对葡萄糖平衡和脂质代谢至关重要.
- GLP-1R激动剂已经成为重要的治疗药物,特别是在治疗2型糖尿病和肥胖症方面.
- 它们的多方面的作用超越了代谢调节,表明了更广泛的临床实用性.
研究的目的:
- 为提供GLP-1受体药物的发展轨迹的全面概述.
- 探索GLP-1受体激活剂 (GLP-1RAs) 的多样化的药理特性和不断发展的临床应用.
- 评估GLP-1RAs在各种生理系统和疾病状态中的疗效.
主要方法:
- 关于GLP-1药物开发的文献综述,从发现到临床使用.
- 分析不同GLP-1药物的药理概况.
- 整合最近关于GLP-1RA有效性的临床试验数据.
- 信号通路和作用机制的探索.
主要成果:
- GLP-1RAs在治疗肥胖,心血管疾病,非酒精性脂肪肝疾病 (NAFLD) 和神经退行性疾病方面表现出显著的治疗疗效.
- 证据支持它们在神经保护,抗感染,减少炎症和增强心血管系统方面的作用.
- GLP-1RAs影响多个系统,包括神经,心血管,肌肉骨和消化系统.
结论:
- GLP-1受体激动剂在传统的代谢应用之外,为广泛的疾病提供了广泛的益处.
- GLP-1药物的适用范围不断扩大,凸显了它们巨大的治疗潜力.
- 进一步的研究和开发有望扩大GLP-1受体激动剂的临床影响.
相关概念视频
Glucagon-like Receptor Agonists
305
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
305
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Oral Hypoglycemic Agents: Glinides
145
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
145
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K


